Ορφανά φάρμακα (FDA) που εισάγονται μέσω ΙΦΕΤ
Ταξινόμηση κατά δραστική ουσία
Επιλέξτε εδώ για να πάρετε αρχείο excel
PRODUCT ACTIVE INGREDIENT Orphan Designation: SPONSOR ΔΙΑΘΕΣΗ
ADAGEN Pegademase Bovine   Enzon, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
ALKERAN For Injection Melphalan For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate. Glaxo Wellcome Inc. STOCK
AMMONUL Benzoate/Phenylacetate Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. Medicis Pharmaceutical Corp. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
CAFCIT Caffeine Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age. O.P.R. Development, L.P. STOCK
CYANOCIT Hydroxocobalamin Treatment on known or suspected cyanide poisoning Merck Sante, s.a.a. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
CYSTADANE Betaine Treatment of homocystinuria to decrease elevated homocysteine blood levels. Jazz Pharmaceuticals ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
CYSTAGON Cysteamine Treatment of nephropathic cystinosis in adults and children. Mylan Laboratories, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
DEPOCYT Cytarabine Liposomal Intrathecal treatment of lymphomatous meningitis. Pacira Pharmaceuticals, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
DIGIBIND Digoxin Immune Fab (Ovine)   Glaxo Wellcome Inc. STOCK
ELMIRON Pentosan Polysulfate Sodium Relief of bladder pain or discomfort associated with interstitial cystitis. Alza Corporation ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
FLOLAN Epoprostenol Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients. Glaxo Wellcome Inc. STOCK
FLOLAN Epoprostenol For the long-term intravenous treatment of pulmonary hypertension associated with the scleroderma spectrum of disease in New York Heart Association (NYHA) Class III and Class IV patients who do not respond adequately to conventional therapy. GlaxoSmithKline LLC STOCK
FOLOTYN Pralatrexate Treatment of patients with relapsed or refractory peripheral T-cell lymphoma Allos Therapeutics, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
GALZIN Zinc Acetate For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent. Lemmon Company ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
LEUKINE Sargramostim Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. Immunex Corporation ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
LIDODERM Patch Lidocaine Patch 5%   Teikoku Pharma USA, Inc. STOCK ΩΣ VERSATIS
LIORESAL Intrathecal Baclofen Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses. Medtronic, Inc. STOCK
MYCOBUTIN Rifabutin Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections. Adria Laboratories, Inc. STOCK
MYLOTARG Gemtuzumab Zogamicin Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy Wyeth-Ayerst Laboratories ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
n/a Desmopressin Acetate Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%. Aventis Behring L.L.C. STOCK ΩΣ DDAVP
NAGLAZYME N-Acetylgalactosamine-4-Sulfatase, Recombinant Human For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity. BioMarin Pharmaceutical, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
ONCASPAR Pegaspargase Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase. Enzon, Inc. STOCK
ONTAK Denileukin Diftitox Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Eisai, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
ORFADIN Nitisinone Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 Rare Disease Therapeutics, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
PASER Granules Aminosalicylic Acid Treatment of tuberculosis Jacobus Pharmaceutical Company ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
RIASTAP Human Fibrinogen Concentrate, Pasteurized Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia CSL Behring, LLC STOCK
RIFADIN I.V. Rifampin   Hoechst Marion Roussel STOCK
SOLIRIS Eculizumab Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis Alexion Pharmaceuticals, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
SULFAMYLON Solution Mafenide Acetate Solution   Mylan Laboratories, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
SYPRINE Trientine Hcl   Merck Sharp & Dohme Research STOCK ΩΣ TRIENTINE
THIOLA Tiopronin   Pak, Charles Y.C. M.D. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ
TREANDA Bendamustine Hydrochloride Treatment of patients with chronic lymphocytic leukemia Cephalon, Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ ΩΣ RIBOMUSTINE
VUMON For Injection Teniposide Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents. Bristol-Myers Squibb Pharmaceutical Research Institute STOCK
XENAZINE Tetrabenazine Treatment of chorea associated with Huntington's disease Prestwick Pharmaceuticals, Inc STOCK
ZOLINZA Vorinostat Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies. Merck & Co., Inc. ΕΙΔΙΚΗ ΠΑΡΑΓΓΕΛΙΑ